Literature DB >> 18566449

Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.

William Stohl1, Noam Jacob, William J Quinn, Michael P Cancro, Huaxin Gao, Chaim Putterman, Xiaoni Gao, Luminita Pricop, Michael N Koss.   

Abstract

In otherwise non-autoimmune-prone C57BL/6 (B6) mice rendered genetically deficient in CD152 (CTLA-4), polyclonal hypergammaglobulinemia with increased levels of systemic lupus erythematosus (SLE)-associated IgG autoantibodies, glomerular IgG and C3 deposition, and interstitial nephritis all developed by 3-5 wk of age. Remarkably, superimposing genetic deficiency of BAFF (B cell-activating factor belonging to the TNF family) onto CD152 deficiency did not substantially attenuate humoral autoimmunity and immunopathology in these mice, despite the resulting marked reduction in B-lineage cells. Although superimposing a BAFF transgene (resulting in constitutive BAFF overexpression) onto CD152-deficient mice did lead to increases in B-lineage cells and serum levels of certain SLE-associated IgG autoantibodies, renal immunopathology remained largely unaffected. Taken together, these results demonstrate that global T cell dysregulation, even in an otherwise non-autoimmune-prone host, can promote systemic humoral autoimmunity and immunopathology in a BAFF-independent manner. Moreover, supraphysiologic expression of BAFF in the setting of ongoing autoimmunity does not necessarily lead to greater immunopathology. These findings may help explain the limited clinical efficacy appreciated to date of BAFF antagonists in human SLE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566449      PMCID: PMC2587218          DOI: 10.4049/jimmunol.181.1.833

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase.

Authors:  T F Gajewski; F Fallarino; P E Fields; F Rivas; M L Alegre
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

2.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

3.  Synthesis and release of B-lymphocyte stimulator from myeloid cells.

Authors:  B Nardelli; O Belvedere; V Roschke; P A Moore; H S Olsen; T S Migone; S Sosnovtseva; J A Carrell; P Feng; J G Giri; D M Hilbert
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

4.  Cutting edge: two distinct mechanisms lead to impaired T cell homeostasis in Janus kinase 3- and CTLA-4-deficient mice.

Authors:  S Gozalo-Sanmillan; J M McNally; M Y Lin; C A Chambers; L J Berg
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

5.  CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease.

Authors:  T Kouki; Y Sawai; C A Gardine; M E Fisfalen; M L Alegre; L J DeGroot
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

6.  NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells.

Authors:  Eunice N Hatada; Richard K G Do; Amos Orlofsky; Hsiou-Chi Liou; Michael Prystowsky; Ian C M MacLennan; Jorge Caamano; Selina Chen-Kiang
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

7.  Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice.

Authors:  S D Khare; I Sarosi; X Z Xia; S McCabe; K Miner; I Solovyev; N Hawkins; M Kelley; D Chang; G Van; L Ross; J Delaney; L Wang; D Lacey; W J Boyle; H Hsu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

8.  BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population.

Authors:  J S Thompson; P Schneider; S L Kalled; L Wang; E A Lefevre; T G Cachero; F MacKay; S A Bixler; M Zafari; Z Y Liu; S A Woodcock; F Qian; M Batten; C Madry; Y Richard; C D Benjamin; J L Browning; A Tsapis; J Tschopp; C Ambrose
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

9.  Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.

Authors:  F Mackay; S A Woodcock; P Lawton; C Ambrose; M Baetscher; P Schneider; J Tschopp; J L Browning
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

10.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  7 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Authors:  Peter J Bugelski; Pauline L Martin
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  CTLA-4 exon 1 +49A/G polymorphism is associated with renal involvement in pediatric Henoch-Schönlein purpura.

Authors:  Jian-Jun Wang; Yan-Ping Shi; Huang Yue; Wu Chun; Li-Ping Zou
Journal:  Pediatr Nephrol       Date:  2012-06-15       Impact factor: 3.714

3.  Macrophages from lupus-prone MRL mice have a conditional signaling abnormality that leads to dysregulated expression of numerous genes.

Authors:  Angelika Antoni; Vimal A Patel; Hanli Fan; Daniel J Lee; Lee H Graham; Cristen L Rosch; Daniel S Spiegel; Joyce Rauch; Jerrold S Levine
Journal:  Immunogenetics       Date:  2011-01-13       Impact factor: 2.846

Review 4.  Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?

Authors:  William Stohl
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 5.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

6.  BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis.

Authors:  Xiaohui Zhou; Zanxian Xia; Qin Lan; Julie Wang; Wenru Su; Yuan-Ping Han; Huimin Fan; Zhongmin Liu; William Stohl; Song Guo Zheng
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

Review 7.  Immunotherapeutic strategies in autoimmune uveitis.

Authors:  Pedro Henrique Papotto; Eliana Blini Marengo; Luiz Roberto Sardinha; Anna Carla Goldberg; Luiz Vicente Rizzo
Journal:  Autoimmun Rev       Date:  2014-05-12       Impact factor: 9.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.